Collaborative Fund Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$307K Sell
2,165
-4,446
-67% -$715K 0.17% 162
2026
Q2
$1.11M Buy
6,611
+3,318
+101% +$492K 0.65% 38
2026
Q1
$434K Buy
+3,293
New +$437K 0.27% 103

Other funds holding NBIX

Collaborative Fund Advisors's NBIX Position: Q3 2026 in Review

Collaborative Fund Advisors reduced its Neurocrine Biosciences (NBIX) stake by 67% in Q3 2026, selling an estimated $715K and leaving 2,165 shares worth $307K. The position accounts for 0.17% of the portfolio, ranked #162.

Collaborative Fund Advisors first reported a position in NBIX in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.11M in Q2 2026. 770 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Collaborative Fund Advisors held 2,165 shares of Neurocrine Biosciences worth $307K as of Q3 2026.
  • Collaborative Fund Advisors sold 4,446 Neurocrine Biosciences shares in Q3 2026, an estimated $715K.
  • Neurocrine Biosciences made up 0.17% of Collaborative Fund Advisors's portfolio in Q3 2026, its #162 holding.
  • Collaborative Fund Advisors first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 3 quarters since.
  • Collaborative Fund Advisors's Neurocrine Biosciences position peaked at $1.11M in Q2 2026.
  • 770 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Collaborative Fund Advisors's 13F filing for Q3 2026, filed 2 Nov 2026.